检索结果-南通市图书馆

Hepatotoxicity induced by cyproterone acetate:A report of three cases

World Journal of Gastroenterology 2006年第46期12卷 7551-7555页

作者： Ioanna Savidou Melanie Deutsch Aspasia S Soultati Dimitrios Koudouras Georgia Kafiri Spyridon P Dourakis 2nd Department of Medicine University of Athens Medical School Hippokration General Hospital 114 Vas Sofias Avenues 11527 Athens Greece Department of Pathology Hippokration General Hospital Greece

cyproterone acetate (CPA) is a steroidal synthetic progestagen and anti-androgenic compound widely administered in prostate cancer which has been evidentially correlated with a severe hepatotoxic potency. Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration. Patients were treated with CPA at the doses of 200-300 mg/d for malignant prostate disease for 3-12 mo prior to the acute manifestation of the hepatic disease. Clinical features compatible with mixed hepatocellular and cholestatic liver disease including jaundice, white stools and dark urine, manifested in all three cases whereas encephalopathy and ascites were present in two of the patients. Other primary causes of hepatotoxicity (alcohol consumption and viral hepatitis) were also verified in two cases, and in those patients biopsy findings revealed the presence of cirrhotic lesions in liver parenchyma. Discontinuation of the therapeutic agent led to the amelioration of the clinical profile in all the patients whereas a patient died 40 d after hospital admission due to sepsis, despite acute liver disease improvement. The current article highlights the hepatotoxic potency of a widely administered therapeutic agent and illustrates the importance of clinical surveillance especially in patients with previous hepatic diseases. Three relevant cases are reported and a review of the published literature is made.

关键词： cyproterone acetate Drug induced hepatotoxicity Prostate cancer Idiosyncratic drug reaction Hepatomitogen action

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Effects of Metformin Combined with cyproterone acetate on Clinical Features, Endocrine and Metabolism of Non-obese Women with Polycystic Ovarian Syndrome

引用

Journal of Huazhong University of Science and Technology(Medical Sciences) 2005年第2期25卷 194-197页

作者：吕立群刘义孙永玉谭侃 Department of Gynecology and Obstetrics Union Hospital Tongji Medical College HuazhongUniversity of Science and Technology Wuhan 430022 China

Summary: In order to explore the effects of metformin combined with cyproterone acetate (CPA) on the clinical features, endocrine and metabolism of the patients with polycystic ovarian syndrome (PCOS), 50 cases of non-obese PCOS were randomly subjected to CPA (CPA treatment group, n=25) and CPA+metformin (n=25) treatment for 6 months. Before and after treatment the body mass index (BMI), waist:hip ratio (WHR), ovarian volume, serum gonadotrophin, androgen and sex hormone-binding globulin (SHBG) levels, and fasting lipid, glucose and insulin levels were measured. The results showed that all of the parameters in two groups were similar before treatment. After treatment for 6 months in the CPA+ metformin group, BMI and WHR were significantly decreased, while insulin sensitivity was significantly decreased as compared with those before treatment. In CPA group, no significant changes were found before and after treatment. Combined use of CPA and metformin could result in the reduction of serum androstenedione and increases of serum SHBG levels as compared with the CPA treatment alone. It was concluded that combined use of CPA and metformin could improve the insulin sensitivity, and further suppress the hyperandrogenism in non-obese women with PCOS.

关键词： cyproterone acetate metformin insulin resistance polycystic ovarian syndrome

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Comparison of Drospirenone-with cyproterone acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders： A Prospective Randomized Control Trial

引用

Chinese Medical Journal 2016年第8期129卷 883-890页

作者： Qiu-Yi Wang Yong Song Wei Huang Li Xiao Qiu-Shi Wang Gui-Mei Feng Department of Obstetrics and Genecology West China Second University Hospital Sichuan University Chengdu Sichuan 610000 China

Background：While combined oral contraceptives （COCs） are commonly used to treat polycystic ovary syndrome （PCOS）,comparative data regarding metabolic effects of different progestogens on this patient population are *** study aimed to compare the different effects of drospirenone （DRP）-containing COCs with cyproterone acetate （CPA）-containing COCs,combined with metformin and lifestyle modifications in women with PCOS and metabolic ***：Ninety-nine women with PCOS and a metabolic disorder between January 2011 and January 2013 were enrolled into this prospective randomized clinical *** were randomized into two groups such as DRP-containing COCs,and CPA-containing *** took COCs cyclically for 6 months,combined with metformin administration （1.5 g/d） and lifestyle modifications （diet and exercise）.Clinical measures and biochemical and hormone profiles were *** for continuous variables were evaluated with paired and unpaired Student＆#39;s *** Wilcoxon signed rank test was used when the data were not normally *** of covariance was used to control for age,body mass index （BMI）,and baseline data of each analyzed parameter when compared between the two ***：A total of 68 patients have completed the *** combination regimen of COCs,metformin,and lifestyle modifications in these patients resulted in a significant decrease in BMI,acne,and hirsutism scores when compared to baseline levels in both groups （P 〈 0.05）.Blood pressure （BP） was significantly different in the CPA group when compared to baseline （75.14 ± 6.77 mmHg vs.80.70 ± 5.60 mmHg,P 〈 0.01）,and after 6 months of treatment,only the change in systolic BP was significantly different between the two groups （4.00 [-6.00,13.00] mmHg vs.-3.50 [-13.00,9.00] mmHg,P =0.009）.Fasting glucose,fasting insulin,and homeostasis model assessment-insulin resistance decreased significantly in the DRP group （5.40 ± 0.41 mmol/L vs.5.

关键词： cyproterone acetate Drospirenone Metabolic Disorder Oral Contraceptives, Combined Polycystic Ovary Syndrome

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

应用微剂量醋酸色布龙(cyproterone acetate)试图导致雄鼠不育的试验遭到失败

引用

国外医学参考资料.计划生育妇产科学分册 1978年第1期 34-35页

作者：刁筱辉

Prasad 等曾报道微剂量醋酸色布龙(CPA)可干扰副睾功能,造成雄鼠可逆性的不育。为了证实这一结果,本文作者应用不同剂量的 CPA 完成了一系列的试验。试验方法是将重量为300～400克、有生育力的雄鼠(Sprague-Dawley 种)100只分成四组,其... 详细信息

Prasad 等曾报道微剂量醋酸色布龙(CPA)可干扰副睾功能,造成雄鼠可逆性的不育。为了证实这一结果,本文作者应用不同剂量的 CPA 完成了一系列的试验。试验方法是将重量为300～400克、有生育力的雄鼠(Sprague-Dawley 种)100只分成四组,其中一组为不用药的对照组,其余三组为给药组,分别皮下植入1枚、3枚、5枚 CPA硅胶管。每枚硅胶管长15毫米,直径6毫米。在第

关键词：雄鼠生育力 cyproterone acetate 微剂量醋酸乙酸

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

可能的男用避孕丸——cyproterone acetate

引用

国外医学参考资料.计划生育妇产科学分册 1977年第1期 25-25页

作者：杨嘉龄

在米兰举行的节制生育讨论会上曾提出关于环丙氯孕酮(cyproterone acetate,)作为男用避孕药物的第一期抗雄激素研究报道。 cyproterone acetate是一种“抗雄激素”。大

关键词：性欲成熟精子抗雄激素 cyproterone acetate

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：